Assembly Biosciences’ (ASMB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a report published on Tuesday,Benzinga reports. They currently have a $50.00 price target on the biopharmaceutical company’s stock.

ASMB has been the topic of a number of other reports. Guggenheim upped their price target on Assembly Biosciences from $31.00 to $39.00 and gave the company a “buy” rating in a report on Monday, September 8th. Citigroup initiated coverage on Assembly Biosciences in a report on Wednesday, September 24th. They set an “outperform” rating on the stock. Citizens Jmp initiated coverage on Assembly Biosciences in a report on Wednesday, September 24th. They set an “outperform” rating and a $38.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, October 8th. Finally, Zacks Research raised Assembly Biosciences to a “hold” rating in a report on Tuesday, August 19th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.25.

Assembly Biosciences Trading Up 2.3%

Shares of NASDAQ:ASMB opened at $29.08 on Tuesday. The stock has a fifty day simple moving average of $24.74 and a two-hundred day simple moving average of $18.17. The stock has a market capitalization of $223.04 million, a price-to-earnings ratio of -5.21 and a beta of 0.60. Assembly Biosciences has a 12-month low of $7.75 and a 12-month high of $29.40.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.73) by $0.40. The business had revenue of $9.63 million during the quarter, compared to analysts’ expectations of $5.30 million. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%. As a group, equities research analysts predict that Assembly Biosciences will post -6.87 EPS for the current year.

Institutional Trading of Assembly Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Ellsworth Advisors LLC purchased a new stake in Assembly Biosciences in the third quarter worth about $852,000. Geode Capital Management LLC increased its position in Assembly Biosciences by 6.9% in the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 3,312 shares in the last quarter. Palumbo Wealth Management LLC increased its position in Assembly Biosciences by 3.8% in the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock worth $338,000 after buying an additional 681 shares in the last quarter. Acadian Asset Management LLC increased its position in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares in the last quarter. Finally, American Century Companies Inc. purchased a new stake in Assembly Biosciences in the first quarter worth about $113,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.